WO2013119258A1 - Systems and apparatus for facilitating intranasal treatment of a patient - Google Patents
Systems and apparatus for facilitating intranasal treatment of a patient Download PDFInfo
- Publication number
- WO2013119258A1 WO2013119258A1 PCT/US2012/027138 US2012027138W WO2013119258A1 WO 2013119258 A1 WO2013119258 A1 WO 2013119258A1 US 2012027138 W US2012027138 W US 2012027138W WO 2013119258 A1 WO2013119258 A1 WO 2013119258A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- catheter
- hub
- sheath
- catheter hub
- insertion end
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 65
- 208000002193 Pain Diseases 0.000 claims abstract description 18
- 208000005298 acute pain Diseases 0.000 claims abstract description 4
- 238000003780 insertion Methods 0.000 claims description 104
- 230000037431 insertion Effects 0.000 claims description 104
- 206010019233 Headaches Diseases 0.000 claims description 47
- 231100000869 headache Toxicity 0.000 claims description 41
- 210000003928 nasal cavity Anatomy 0.000 claims description 30
- 230000008878 coupling Effects 0.000 claims description 22
- 238000010168 coupling process Methods 0.000 claims description 22
- 238000005859 coupling reaction Methods 0.000 claims description 22
- 210000001519 tissue Anatomy 0.000 claims description 14
- 208000004296 neuralgia Diseases 0.000 claims description 10
- 230000007704 transition Effects 0.000 claims description 10
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims description 9
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims description 9
- 208000005392 Spasm Diseases 0.000 claims description 9
- 230000002567 autonomic effect Effects 0.000 claims description 9
- 208000007514 Herpes zoster Diseases 0.000 claims description 8
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 7
- 208000006373 Bell palsy Diseases 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 206010040744 Sinus headache Diseases 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000001319 vasomotor rhinitis Diseases 0.000 claims description 6
- 208000008930 Low Back Pain Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000008035 Back Pain Diseases 0.000 claims description 4
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 4
- 206010002091 Anaesthesia Diseases 0.000 claims description 3
- 206010006002 Bone pain Diseases 0.000 claims description 3
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 3
- 208000014181 Bronchial disease Diseases 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 206010006482 Bronchospasm Diseases 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 3
- 208000001387 Causalgia Diseases 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 208000031108 Chronic hiccup Diseases 0.000 claims description 3
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 3
- 208000006561 Cluster Headache Diseases 0.000 claims description 3
- 208000012514 Cumulative Trauma disease Diseases 0.000 claims description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 3
- 201000009273 Endometriosis Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims description 3
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims description 3
- 206010049977 Intracranial hypotension Diseases 0.000 claims description 3
- 208000007101 Muscle Cramp Diseases 0.000 claims description 3
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 3
- 208000004983 Phantom Limb Diseases 0.000 claims description 3
- 206010056238 Phantom pain Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 206010037779 Radiculopathy Diseases 0.000 claims description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 208000008765 Sciatica Diseases 0.000 claims description 3
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 3
- 206010043269 Tension headache Diseases 0.000 claims description 3
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 3
- 208000009205 Tinnitus Diseases 0.000 claims description 3
- 206010044074 Torticollis Diseases 0.000 claims description 3
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 230000037005 anaesthesia Effects 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 208000036319 cervical spondylosis Diseases 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 3
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 3
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 208000018197 inherited torticollis Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000030062 persistent idiopathic facial pain Diseases 0.000 claims description 3
- 230000002980 postoperative effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000001148 spastic effect Effects 0.000 claims description 3
- 208000005198 spinal stenosis Diseases 0.000 claims description 3
- 208000005801 spondylosis Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 231100000886 tinnitus Toxicity 0.000 claims description 3
- 208000004371 toothache Diseases 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims 1
- 210000000609 ganglia Anatomy 0.000 description 38
- 238000000034 method Methods 0.000 description 37
- 210000001944 turbinate Anatomy 0.000 description 18
- 239000003814 drug Substances 0.000 description 14
- 230000036407 pain Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 210000005036 nerve Anatomy 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- 239000003589 local anesthetic agent Substances 0.000 description 12
- 230000003444 anaesthetic effect Effects 0.000 description 9
- 208000003098 Ganglion Cysts Diseases 0.000 description 8
- 208000005400 Synovial Cyst Diseases 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000003128 head Anatomy 0.000 description 6
- 210000000537 nasal bone Anatomy 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 210000003484 anatomy Anatomy 0.000 description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 238000011221 initial treatment Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 208000027109 Headache disease Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000009958 parasympathetic pathway Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 210000000598 pterygopalatine fossa Anatomy 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000018316 severe headache Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/24—Surgical instruments, devices or methods, e.g. tourniquets for use in the oral cavity, larynx, bronchial passages or nose; Tongue scrapers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00292—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means
- A61B2017/003—Steerable
- A61B2017/00318—Steering mechanisms
- A61B2017/00331—Steering mechanisms with preformed bends
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/0042—Surgical instruments, devices or methods, e.g. tourniquets with special provisions for gripping
- A61B2017/00455—Orientation indicators, e.g. recess on the handle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/08—Accessories or related features not otherwise provided for
- A61B2090/0807—Indication means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/08—Accessories or related features not otherwise provided for
- A61B2090/0807—Indication means
- A61B2090/0811—Indication means for the position of a particular part of an instrument with respect to the rest of the instrument, e.g. position of the anvil of a stapling instrument
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0041—Catheters; Hollow probes characterised by the form of the tubing pre-formed, e.g. specially adapted to fit with the anatomy of body channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0097—Catheters; Hollow probes characterised by the hub
Definitions
- the SPG is a collection of nerve cells resting just beneath the thin tissues that line the back of the nasal passage. Because of the neural connections that pass through it, the SPG plays an essential role in various types of headaches. Temporary interruption of impulse conduction through the SPG can often abort headaches and sometimes provide long-term relief to headache sufferers. [0005] Other conditions shown to respond to SPGB in published literature include: trigeminal neuralgia, dental pain, post-partum neck and back pain, complex regional pain syndrome, herpes zoster (Shingles), tempromandibular joint (TMJ) pain and primary hyperhidrosis, among other indications, as discussed herein and claimed below.
- Accessing the SPG/pterygopalatine recess to treat the SPG/pterygopalatine ganglia with a conventional device is difficult in that a conventional devices typically do not include a curvature for accessing the sphenopalatine/pterygopalatine recess. Further, even if a conventional needle were curved to access the sphenopalatine/pterygopalatine recess, once the curved needle were inserted into the patient's nasal cavity, the physician or other medical professional would not be able to identify the direction of the curve of the needle. Without fluoroscopic guidance, an insertion end of the needle may contact and/or damage the vital and delicate mid brain structures. To date, this limitation has limited both service-providers and patients from being involved to a large extent.
- the present subject matter has been developed in response to the present state of the art, and in particular, in response to the problems and needs in the art that have not yet been fully solved by currently available intranasal treatment apparatus, systems, and methods. Accordingly, the present subject matter has been developed to provide an apparatus and system, for intranasal treatment of a patient that overcome many or all of the above-discussed shortcomings in the art.
- the apparatus to facilitate intranasal treatment of a patient's SPG/pterygopalatine recess includes, in certain embodiments, a sheath hub, a catheter hub, an arresting element, and an engagement element.
- the sheath hub has an exterior surface opposing an interior surface. The interior surface defines a catheter hub receiving space.
- the catheter hub is slideably received within the catheter hub receiving space and is positionable along a longitudinal axis of the sheath hub.
- the arresting element is positioned on one of the catheter hub and the sheath hub and the engagement element is positioned on the other of the catheter hub and the sheath hub.
- the arresting element continuously engages the engagement element when the catheter hub is positioned along the longitudinal axis of the sheath hub. Engagement between the arresting element and the engagement element prevents rotation of the sheath hub with respect to the catheter hub.
- the apparatus in one embodiment, includes a catheter and a rotational orientation indicator.
- the catheter is coupled to the catheter hub and at least a portion of the catheter includes an intrinsic curvature.
- the rotational orientation indicator identifies the rotational orientation of the intrinsic curvature of the catheter.
- the rotational orientation indicator comprises a raised ridge extending longitudinally along at least one of the sheath hub and the catheter hub. In other embodiments, the rotational orientation indicator only provides a visual indication of the rotational orientation of the intrinsic curvature of the catheter.
- the catheter includes an insertion end and a coupling end.
- the insertion end may include the intrinsic curvature with respect to a longitudinal axis of the catheter and the rotational orientation indicator identifies the rotational orientation of the intrinsic curvature of the catheter.
- the apparatus includes a sheath coupled to the sheath hub and a catheter coupled to the catheter hub and received within the sheath.
- the catheter includes an insertion end and a coupling end with the insertion end having an intrinsic curvature with respect to a longitudinal axis of the catheter.
- the catheter hub is positionable between an inserted position and an extended position. With the catheter hub positioned in the extended position, the sheath straightens the intrinsic curvature of the catheter.
- the catheter in some embodiments, includes an insertion end having a tip that is curved such that the tip is rounded.
- the sheath includes an introduction end having an outermost edge that is sloped to a vertex.
- the vertex aligns with a beginning of the curve of the rounded tip of the catheter.
- a transition between the vertex and the beginning of the curve of the rounded tip of the catheter is continuous when the catheter hub is positioned in the extended position.
- a tip of the insertion end of the catheter is bulbous.
- the arresting element in certain embodiments, is a flange coupled to and extending perpendicularly from either an outer surface of the catheter hub or an interior surface of the sheath hub.
- the engagement element is a recess extending longitudinally along the other of the interior surface of the sheath hub or the outer surface of the catheter hub.
- the flange is positioned within and travels along the recess when the catheter hub is repositioned along the longitudinal axis of the sheath hub.
- the apparatus includes a stopping element coupled to either the catheter hub or the sheath hub.
- the stopping element is configured to engage the arresting element to stop the catheter hub from being removed from the catheter hub receiving space.
- the stopping element is configured to align the vertex of the sheath with the beginning of the curve of the rounded tip of the catheter when the catheter hub is positioned in the extended position.
- the apparatus includes a sheath hub, a catheter hub, an arresting element, an engagement element, and a rotational orientation indicator.
- the sheath hub has an exterior surface opposing an interior surface. The interior surface defines a catheter hub receiving space.
- the catheter hub is slideably received within the catheter hub receiving space and is positionable along a longitudinal axis of the sheath hub.
- the arresting element is coupled to or positioned on either the catheter hub or the sheath hub.
- the engagement element is coupled to or positioned one or in the other of the catheter hub and the sheath hub.
- the arresting element continuously engages the engagement element when the catheter hub is repositioned along the longitudinal axis of the sheath hub. Engagement between the arresting element and the engagement element prevents rotation of the sheath hub with respect to the catheter hub.
- the rotational orientation indicator identifies a rotational orientation of at least one of the sheath hub and the catheter hub.
- the rotational orientation indicator is a raised ridge extending longitudinally along at least one of the sheath hub and the catheter hub.
- the raised ridge identifies the rotational orientation of at least one of the sheath hub and the catheter hub both visually and tactilely.
- the apparatus includes a catheter coupled to the catheter hub.
- the catheter has an insertion end and a coupling end, with the insertion end having an intrinsic curvature with respect to a longitudinal axis of the catheter.
- the rotational orientation indicator identifies an orientation of the intrinsic curvature of the catheter.
- the arresting element in certain embodiments, includes a flange coupled to and extending perpendicularly from either an outer surface of the catheter hub or an interior surface of the sheath hub.
- the engagement element includes a recess extending longitudinally along the other of the interior surface of the sheath hub and the outer surface of the catheter hub.
- the flange of the arresting element is positioned within and travels along the recess of the engagement element when the catheter hub is repositioned along the longitudinal axis of the sheath hub.
- the apparatus further includes a sheath coupled to the sheath hub and the catheter hub is positionable between an inserted position and an extended position.
- the sheath straightens the intrinsic curvature of the catheter.
- a tip of the insertion end of the catheter is curved such that the tip is rounded.
- the sheath includes an introduction end and a connected end. An outermost edge of the introduction end is sloped to a vertex and the vertex aligns with a beginning of the curve of the rounded tip of the catheter when the catheter hub is repositioned within the sheath hub to the extended position.
- An apparatus for facilitating intranasal treatment of a patient's SPG/pterygopalatine recess which includes a sheath hub, a catheter hub, an arresting element, an engagement element, a sheath, and a catheter.
- the sheath hub has an exterior surface opposing an interior surface. The interior surface defines a catheter hub receiving space and the catheter hub is slideably received within the catheter hub receiving space.
- the catheter hub is positionable along a longitudinal axis of the sheath hub.
- the arresting element is positioned on either the catheter hub or the sheath hub.
- the engagement element is positioned on or in the other of the catheter hub or the sheath hub.
- the arresting element continuously engages the engagement element when the catheter hub is repositioned along the longitudinal axis of the sheath hub between an inserted position and an extended position.
- the sheath is coupled to the sheath hub and includes an introduction end having an outermost edge.
- the catheter is received within the sheath and is coupled to the catheter hub.
- the catheter includes an insertion end having a tip that is curved such that the tip is rounded. The outermost edge of the sheath aligns with a beginning of the curve of the rounded tip of the catheter when the catheter hub is positioned in the extended position.
- the outermost edge of the introduction end of the sheath is sloped to a vertex.
- the vertex aligns with the beginning of the curve of the rounded tip of the catheter when the catheter is positioned in the extended position.
- a transition between the vertex and the beginning of the curve of the rounded tip of the catheter is continuous when the catheter hub is positioned in the extended position.
- the tip of the insertion end of the catheter is bulbous. In such an embodiment, the bulbous tip of the insertion end of the catheter may shield the sheath to prevent the sheath from snagging delicate tissues within the patient's nasal cavity.
- a system and apparatus for addressing acute pain wherein indications exist for at least one of head and neck cancer, Complex regional pain syndrome, Reflex Sympathetic Dystrophy, Vasomotor rhinitis, Pre- and postoperative anesthesia in oral and maxillofacial surgery, Cluster Headache, Cephalgia, Cervical Spasm, Disc Disease or Herniation, Any Level, Lumbago, Lumbosacral Spasm, Pyriformis Spasm Syndrome, Spastic (Spasmodic) Torticollis, SPG Neuralgia (Sluder's Syndrome), Trigeminal Neuralgia (Tic Douleureux), Post-Herpetic Neuralgia, Autonomic Neuralgia, Atypical Facial Pain, Bulging Disc, Lumbosacral Disc, Causalgia, Reflex Sympathetic Dystrophy (RSD), Cervical Spondylosis, Migraine Headache, Sinus Head
- Figure 1 is a cutaway view illustrating one embodiment of the facial anatomy of a patient upon which the apparatus, system and method of the present invention may be employed;
- Figure 2 is a cutaway view illustrating a prior art method of treating headaches
- Figure 3 is a cutaway view illustrating a prior art method of treating headaches
- Figure 5 A is a top view illustrating one embodiment of an apparatus for facilitating intranasal treatment of a patient's sphenopalatine/pterygopalatine recess with a catheter hub positioned in an extended position within a sheath hub (ready for device insertion) in accordance with the present subject matter;
- Figure 5B is a side cutaway view illustrating one embodiment of an apparatus for facilitating intranasal treatment of a patient's sphenopalatine/pterygopalatine recess with a catheter hub positioned in an extended position within a sheath hub (ready for device insertion) in accordance with the present subject matter;
- Figure 6 A is a top view illustrating one embodiment of an apparatus for facilitating intranasal treatment of a patient's sphenopalatine/pterygopalatine recess with a catheter hub positioned in an inserted position within a sheath hub (ready for medication delivery) in accordance with the present subject matter;
- Figure 6B is a side cutaway view illustrating one embodiment of an apparatus for facilitating intranasal treatment of a patient's sphenopalatine/pterygopalatine recess with a catheter hub positioned in an inserted position within a sheath hub (ready for medication delivery) in accordance with the present subject matter;
- Figure 7 is a perspective view illustrating one embodiment of a catheter hub in accordance with the present subject matter.
- Figure 8A is a top view illustrating one embodiment of a catheter hub and a catheter in accordance with the present subject matter
- Figure 8B is a side cutaway view illustrating one embodiment of a catheter hub and a catheter in accordance with the present subject matter
- Figure 9A is an end view depicting one embodiment of a catheter hub taken in the direction of the treatment receiving end of the catheter hub in accordance with the present subject matter
- Figure 9B is an end view depicting one embodiment of a catheter hub taken in the direction of the treatment delivery end of the catheter hub in accordance with the present subject matter;
- Figure 1 OA is a top view illustrating one embodiment of a sheath hub and a sheath in accordance with the present subject matter
- Figure 10B is a side cutaway view illustrating one embodiment of a sheath hub and a sheath in accordance with the present subject matter
- Figure 11 is an enlarged view of an area of the sheath hub which includes the stopping element in accordance with the present subject matter
- Figure 12 is an end view depicting one embodiment of the sheath hub taken in the direction of the sheath receiving end of the sheath hub in accordance with the present subject matter
- Figure 13 A is a cutaway view illustrating one embodiment of an introduction end of the sheath and an insertion end of the catheter with a vertex of the sheath aligning with a beginning of a curve of the insertion end of the catheter;
- Figure 13B is a cutaway view illustrating one embodiment of an introduction end of the sheath and an insertion end of the catheter with a vertex of the sheath out of alignment with a beginning of a curve of the insertion end of the catheter;
- Figure 13C is a cutaway view illustrating one embodiment of an introduction end of the sheath and an insertion end of the catheter with a vertex of the sheath out of alignment with a beginning of a curve of the insertion end of the catheter.
- the SphenoCathTM brand of medical device when used as designed, allows any practitioner the directional control necessary to deliver an appropriate dose of medication safely and painlessly to the SPG in an office setting without needles, sedation or narcotics.
- Figure 1 is an illustration of one environment in which the present devices and system operate.
- Figure 1 depicts a cutaway view of the anatomical features of a typical human nasal cavity.
- the mouth 106 is illustrated with teeth 108 and tongue 110.
- the anatomical structures relevant to one practice of the current subject matter include the palate 100 which separates the oral cavity 102 from the nasal cavity 104, the inferior sinus turbinate 112, the middle sinus turbinate 114 and the superior sinus turbinate 116 as well as the nasal bone 122.
- the middle sinus turbinate 114 and superior sinus turbinate 116 define the sphenopalatine/pterygopalatine recess 118. Deep within the sphenopalatine/pterygopalatine recess 118 at the posterior 124 of the sphenopalatine/pterygopalatine recess 118 lies the sphenopalatine/pterygopalatine ganglia 120.
- the sphenopalatine/pterygopalatine ganglia 120 is a neuronal structure located principally in the center of the head in the pterygopalatine fossa posterior to the middle turbinate 114.
- the sphenopalatine/pterygopalatine ganglia 120 comprises the largest cluster of sympathetic neurons in the head outside of the brain.
- the sphenopalatine/pterygopalatine ganglia 120 interfaces and directs nerve impulses to the majority of the head's autonomic or parasympathetic pathways. Therefore, any abnormality or injury to this structure may cause severe pain.
- a nerve block of the sphenopalatine/pterygopalatine ganglia 120 may be effective in relieving a variety of pain conditions ranging from headache to lower back pain. Additionally, other disease processes such as headache disorders and other neurological conditions can be arrested, or improved by local anesthetic blockade, and/or other pharmacological augmentation or mechanical alteration of the sphenopalatine/pterygopalatine ganglia 120 and surrounding structures. [0062] Unfortunately, because of the anatomical position of the sphenopalatine/pterygopalatine ganglia 120, the structure may be very difficult to block with a local anesthetic solution using some commonly practiced techniques.
- the anatomical location of the sphenopalatine/pterygopalatine ganglia 120 is dangerously close to many vital and delicate mid-brain structures.
- direct needle placement can be employed under fluoroscopic guidance to administer anesthetic to the sphenopalatine/pterygopalatine ganglia 120, most practitioners will not attempt the procedure due to the technical difficulty and extreme dangers of an aberrant needle placement.
- the sphenopalatine/pterygopalatine ganglia 120 lies deep within the sphenopalatine/pterygopalatine recess 118.
- Conventional methods undertaken by pain specialists, neurologists, and neurosurgeons include the use of an eight inch cotton-tipped applicator 200 saturated with a local anesthetic. Because a cotton-tipped applicator 200 is used, the procedure is referred to as the "Q-tip" procedure. The cotton-tipped applicator 200 is soaked in a vial of concentrated local anesthetic solution.
- the anesthetic solution is lidocaine, cocaine, etidocaine or prilocaine, or other non-specified local anesthetic agents.
- the cotton-tipped applicator 200 is then advanced into the nostril 202 and through the nasal cavity 104.
- the cotton-tipped applicator 200 must be advanced into the nasal cavity 104 past the middle sinus turbinate 114 and into the sphenopalatine/pterygopalatine recess 118.
- Figure 3 illustrates the tortuous path the cotton-tipped applicator 200 of the prior art must traverse to reach the sphenopalatine/pterygopalatine recess 118.
- the patient is placed in a supine position.
- the cotton-tipped applicator 200 is soaked in a vial of concentrated local anesthetic solution or other pharmacologic agent. The physician then inserts the cotton-tipped applicator 200 into the patient's nostril 202 and through the nasal cavity 104.
- Advancing the straight, rigid cotton-tipped applicator 200 into the sphenopalatine/pterygopalatine recess 118 can be difficult and painful for the patient as the cotton-tipped applicator 200 must be inserted almost parallel to the patient's face to clear the anterior ridge 302 of the middle sinus turbinate 114.
- the cotton-tipped applicator 200 must then make an almost 90° bend to avoid the inferior surface 304 of the nasal bone 122 and access the sphenopalatine/pterygopalatine recess 118.
- the cotton-tipped applicator 200 is left in the patient's sphenopalatine/pterygopalatine recess 118 for approximately 20 minutes to allow diffusion of the local anesthetic or other pharmacologic agent through the sinus mucosa to modulate the sphenopalatine/pterygopalatine ganglia 120 to temporarily block or permanently ablate nerve transmission.
- Anesthetic blockade of any neuronal structure requires direct physical interaction between the anesthetic solution and the targeted tissue. Therefore, to work, the cotton-tipped applicator 200 must deliver the anesthetic solution directly to the sphenopalatine/pterygopalatine ganglia 120. The correct placement of the cotton-tipped applicator 200 is technically challenging and many practitioners simply miss the desired structure, the sphenopalatine/pterygopalatine ganglia 120 when attempting to perform the procedure.
- Figure 4A depicts a perspective view of one embodiment of an apparatus 400 for facilitating intranasal treatment of a patient's sphenopalatine/pterygopalatine recess 118.
- the apparatus 400 in certain embodiments, includes the sheath hub 402, the catheter hub 404, a catheter 412, and a sheath 420.
- the apparatus 400 of Figure 4 A is depicted with a catheter hub 404 positioned in an inserted position 424 within a sheath hub 402.
- Figure 4B depicts a perspective view of one embodiment of the apparatus 400 of Figure 4 A with the catheter hub 404 positioned in an extended position 426 within the sheath hub 402.
- the sheath hub 402 includes an exterior surface 406 that opposes an interior surface 502 (Figure 5B).
- the interior surface 502 of the catheter hub 404 defines a catheter hub receiving space 504 ( Figure 5B).
- At least a portion 422 of the catheter hub 404 is received within the catheter hub receiving space 504 and the catheter hub 404 is repositionable along a longitudinal axis 428 of the sheath hub 402.
- the catheter hub 404 is repositionable between an inserted position 424 as illustrated in Figure 4A and an extended position 426 as illustrated in Figure 4B.
- the catheter hub 404 includes a stopping surface 425.
- the stopping surface 425 of the catheter hub 404 contacts the sheath hub 402 to arrest further insertion of the catheter hub 404 within the catheter hub receiving space 504.
- the catheter hub 404 With the catheter hub 404 fully positioned within the catheter hub receiving space 504 to the point where the stopping surface 425 contacts the sheath hub 402, the catheter hub 404 may be considered to be positioned in the fully inserted position 424 with the internal catheter being fully extended beyond the distal tip of the sheath.
- the catheter hub 404 may be considered to be positioned in a fully extended position 426.
- the profile of the sheath hub 402 and the profile of the catheter hub 404 are substantially circular.
- the sheath hub 402 and the catheter hub 406 may have a triangular profile, a square profile, a rectangular profile, an octagonal profile, an oblong profile, or a profile having any other geometric shape.
- a catheter 412 is coupled to the catheter hub 404 at a coupling end 506 (see Figure 5B) of the catheter 412.
- An insertion end (distal tip) 414 of the catheter 412 includes an intrinsic curvature 416 with respect to a longitudinal axis 418 of the catheter 412.
- the insertion end 414 of the catheter 412 is disposed opposite the coupling end 506 of the catheter 412.
- the intrinsic curvature 416 of the insertion end 414 of the catheter 412 causes the insertion end 414 of the catheter 412 to bend when advanced beyond the distal tip of the sheath 420.
- the intrinsic curvature 416 of the insertion end 414 is retracted into the sheath 420 until the physician or other medical professional advances the catheter beyond the distal tip of the sheath 420 into the space directly above the patient's sphenopalatine/pterygopalatine recess 118 without contacting the delicate surrounding structures of the patient's nasal cavity 104.
- the catheter 412 is coupled to the catheter hub 404 and the sheath 420 is coupled to the sheath hub 402, when the catheter hub 404 is positioned in the extended position 426 the catheter 412 is withdrawn into the sheath 420 as illustrated in Figure 4B. With the catheter 412 withdrawn into the sheath 420, the structural rigidity of the sheath 420 straightens the intrinsic curvature 416 of the insertion end 414 of the catheter 412 allowing the physician or other medical professional to manipulate the insertion end 414 of the catheter 412 past the anterior ridge 302 of the middle sinus turbinate 114.
- the physician or other medical professional can advance the catheter hub 404 to the inserted position 424.
- the catheter hub 404 With the catheter hub 404 repositioned in the inserted position 424 the intrinsic curvature 416 of the insertion end 414 of the catheter 412 is not positioned within the sheath 420 and is therefore not straightened by the sheath 420.
- the intrinsic curvature 416 of the insertion end 414 of the catheter 412 causes the insertion end 414 of the catheter 412 to bend.
- the bend in the catheter 412 allows the physician or other medical professional to direct the insertion end 414 of the catheter 412 into the patient's sphenopalatine/pterygopalatine recess 118 where the physician or other medical professional can deliver treatment to the patient's sphenopalatine/pterygopalatine ganglia 120.
- the apparatus 400 may be used to access other areas of a patient.
- the apparatus 400 may be used by a physician or other medical professional to position the insertion end 414 of the catheter 412 in any area on the patient that is not linear disposed with reference to the entry point. Examples of such areas may include a patient's aural cavity, veins, arteries, etc.
- the treatment delivered may be a dispensing of a nerve blockage to the sphenopalatine/pterygopalatine ganglia 120 through the catheter 412.
- the catheter 412 may include an electrode configured to deliver an electrical stimulation to the sphenopalatine/pterygopalatine ganglia 120.
- One of skill in the art will recognize other medical treatments may be delivered to the sphenopalatine/pterygopalatine ganglia 120.
- the physician or other medical professional inserts the insertion end of the catheter 412 into the patient's nasal cavity
- the physician's or other medical professional's view of the insertion end 414 of the catheter 412 may be obstructed by the surrounding structure of the patient's nose. Accordingly, the physician or other medical professional cannot see the orientation of the intrinsic curvature 416 or insertion end 414 of the catheter 412 to determine whether or not the intrinsic curvature 416 is oriented in a position to advance the insertion end 414 of the catheter 412 into the patient's sphenopalatine/pterygopalatine recess 118.
- the apparatus 400 includes a rotational orientation indicator 408.
- the rotational orientation indicator 408 identifies a rotational orientation of the intrinsic curvature 416 of the catheter 412 to aid the physician or other medical professional in determining the orientation of the insertion end 414 of the catheter.
- the rotational orientation indicator 408 may be a visual indicator such as a line, a dot, or other indication, positioned on an exterior surface 406 of the sheath hub 402, an exterior surface 410 of the catheter hub 404, or both.
- the rotational orientation indicator 408 includes a first rotational orientation indicator 408a positioned on an exterior surface 406 of the sheath hub 402 and a second rotational orientation indicator 408b positioned on an external surface 410 of the catheter hub 404.
- only one of the sheath hub 402 or the catheter hub 404 includes a rotational orientation indicator 408.
- the rotational orientation indicator 408a on the sheath hub 402 is a raised ridge 432 that extends longitudinally along at least a portion of the sheath hub 402.
- the raised ridge 432 extends substantially perpendicularly from the exterior surface 406 of the sheath hub 402 to provide a physician or other medical professional tactile feedback as to the orientation of the intrinsic curvature 416 of the catheter 412.
- the physician or other medical professional can focus their visual attention on other factors that may affect the procedure such as the depth of the catheter 412 within the patient's nasal cavity 104.
- the rotational orientation indicator 408b on the catheter hub 404 may also be a raised ridge 434.
- the raised ridge 434 extends longitudinally along at least a portion of the catheter hub 404.
- the raised ridge 432 extends substantially perpendicularly from the exterior surface 410 of the catheter hub 404 to provide a physician or other medical professional tactile feedback as to the orientation of the intrinsic curvature 416 of the catheter 412.
- both the sheath hub 402 and the catheter hub 404 include raised ridges 432 and 434 that act as rotational orientation indicators 408, the physician or other medical professional can determine the orientation of the intrinsic curvature 416 of the catheter 412 regardless of which component (the catheter hub 404 or the sheath hub 402) the physician or other medical professional is manipulating.
- the raised ridges 432 and 434 on the sheath hub 402 and the catheter hub 404 are aligned along the same axis. In other embodiments, the raised ridge 432 on the sheath hub 402 may be offset from the raised ridge 434 on the catheter hub 404. In yet another embodiment, as discussed above, only one of the sheath hub 402 or the catheter hub 404 includes a rotational orientation indicator 408. In such an embodiment, the apparatus 400 may include either raised ridge 432 on the exterior surface 406 of the sheath hub 402 or raised ridge 434 on the exterior surface 410 of the catheter hub 404.
- the apparatus 400 includes a treatment receiving port 436 that receives a medicinal treatment.
- the treatment receiving port 436 is coupleable to a syringe or other medication delivery device.
- the treatment receiving port 436 is communicable in fluid communication with the catheter 412 such that medication can be delivered through the catheter 412 to the sphenopalatine/pterygopalatine ganglia 120.
- other treatment delivery devices may be coupled to the treatment receiving port 436.
- the treatment delivery device may include an electrical stimulation device configured to transmit an electrical current to the apparatus 400.
- the catheter 412 may include an electrical conduit that conducts a flow of electricity from the treatment receiving port 436 to the insertion end 414 of the catheter 412.
- An electrode positioned on the insertion end 414 of the catheter 412 delivers the electrical current to the patient.
- Figure 5A depicts a top view of one embodiment of an apparatus 400 for facilitating intranasal treatment of a patient's sphenopalatine/pterygopalatine recess 118.
- the catheter hub 404 is positioned in the extended position 426.
- the sheath 420 includes an introduction end 505 that is sloped to a vertex 508 such that the entire introduction end 505 of the sheath 420 forms a smooth slope without any edges to catch on the tissue of the patient's nasal cavity 104.
- the insertion end 414 of the catheter 412 is curved such that a tip 510 of the insertion end 414 of the catheter 412 is rounded.
- a tip 510 of the insertion end 414 of the catheter 412 is rounded.
- the vertex 508 at the introduction end 505 of the sheath 420 aligns with a beginning of the curve of the rounded tip 10 of the catheter 412 such that a transition 512 between the catheter 412 and the sheath 420 is continuous, smooth and substantially edge free.
- a smooth transition 512 between the catheter 412 and the sheath 420 helps to avoid catching tissue within the patient's nasal cavity 104.
- the treatment receiving port 436 includes a coupling member 514 for coupling the apparatus 400 to the treatment delivery device.
- the coupling member 514 may be a plurality of threads disposed around the circumference of the treatment receiving port 436. The threads of the coupling member 514 engage threads on a syringe or other treatment delivery device to couple the treatment delivery device to the treatment receiving port 436.
- Figure 5B depicts a side cutaway view of one embodiment of an apparatus 400 for facilitating intranasal treatment of a patient's sphenopalatine/pterygopalatine recess 118.
- the catheter hub 404 is positioned in the extended position 426.
- the embodiment depicted in Figure 5B is taken along line A-A of Figure 5A and more clearly illustrates one embodiment of the interior surface 502 of the sheath hub 402 and the catheter hub receiving space 504.
- the sheath hub 402 has an exterior surface 406 that opposes an interior surface 502.
- the interior surface 502 of the sheath hub 402 defines a catheter hub receiving space 504.
- a portion 422 of the catheter hub 404 has a reduced diameter and is slideably received within the catheter hub receiving space 504 such that the catheter hub 404 is repositionable in a lengthwise direction along the longitudinal axis 428 (see Figures 4A and 4B) of the sheath hub 402.
- the apparatus 400 includes an arresting element 516 on either the catheter hub 404 or the sheath hub 402.
- the arresting element 516 is a flange that is coupled to and extends perpendicularly from an outer surface 518 of the reduced diameter portion 422 of the catheter hub 404.
- the apparatus 400 also includes an engagement element 520 on either the catheter hub 404 or the sheath hub 402.
- the engagement element 520 is a recess extending longitudinally along the interior surface 502 of the sheath hub 402.
- the flange of the arresting element 516 is positioned within and travels along the recess of the engagement element 520 when the catheter hub 404 is repositioned along the longitudinal axis 428 of the sheath hub 402.
- Cooperation between the arresting element 16 and the engagement element 520 allows the catheter hub 404 to be slideably received within the catheter hub receiving space 504 while limiting rotation of the catheter hub 404 with respect to the sheath hub 402.
- the flange of the arresting element 516 is continuously engaged within the recess of the engagement element 520 when the catheter hub 404 is repositioned within along the longitudinal axis 428 of the sheath hub 402. Engagement between the arresting element 516 and the engagement element 520 prevents rotation of the sheath hub 402 with respect to the catheter hub 404.
- the physician or other medical professional can determine the orientation of intrinsic curvature 414 of the catheter 412 by the position of the rotational orientation indicator 408a on the catheter hub 404 and the rotational orientation indicator 408b on the sheath hub 402 may be unnecessary.
- the apparatus 400 also includes a stopping element 522 coupled to either the catheter hub 404 or the sheath hub 402.
- the stopping element 522 is configured to engage the arresting element 516 to stop the catheter hub 404 from being removed from the catheter hub receiving space 504.
- the stopping element 522 is a substantially rigid wall that engages the arresting element 16 to stop the catheter hub 404 from being removed from the catheter hub receiving space 504.
- the stopping element 522 also facilitates alignment of the vertex 508 at the introduction end 505 of the sheath 420 with the beginning of the curve of the rounded tip 510 of the catheter 412 such that the transition 512 between the catheter 412 and the sheath 420 is continuous, smooth and substantially edge free when the catheter hub 404 is positioned in the extended position 426.
- the position of the arresting element 516, the engagement element 520, and the stopping element 522 may be reversed.
- the arresting element 516 may be coupled to the interior surface 502 of the sheath hub 402 and the recess of the engagement element 520 may be positioned in the outer surface 18 of the reduced diameter portion 506 of the catheter hub 404.
- the stopping element 522 may be coupled to the reduced diameter portion 506 of the catheter hub 404 to restrict the catheter hub 404 from being removed from within the catheter hub receiving space 504 in the sheath hub 402.
- Figure 6A depicts a top view of one embodiment of an apparatus 400 for facilitating intranasal treatment of a patient's sphenopalatine/pterygopalatine recess 118.
- the catheter hub 404 is positioned in the inserted position 424.
- Figure 6B is a side cutaway view of one embodiment of an apparatus for facilitating intranasal treatment of a patient's sphenopalatine/pterygopalatine recess 118.
- the catheter hub 404 is positioned in the inserted position 424.
- the embodiment depicted in Figure 6B is taken along line B-B of Figure 6A.
- the stopping surface 425 of the catheter hub 404 contacts an end 602 of the sheath hub 402 to arrest further insertion of the catheter hub 404 within the catheter hub receiving space 504.
- an end 604 of the reduced diameter portion 422 of the catheter hub 404 contacts an interior wall 606 within the catheter hub receiving space 504 to arrest further insertion of the catheter hub 404 within the catheter hub receiving space 504.
- Figure 7A depicts a perspective view of one embodiment of a catheter hub 404 according to the present disclosure.
- the sheath hub 402 and the catheter 412 have been omitted to better illustrate the catheter hub 404.
- the catheter hub 404 includes a treatment receiving end 702 disposed opposite a treatment delivery end 704.
- the catheter hub 404 includes a manipulation portion 706, an insertion portion 708, and a coupling portion 710.
- the manipulation portion 706, the insertion portion 708, and the coupling portion 710 are substantially cylindrical.
- the manipulation portion 706, the insertion portion 708, and/or the coupling portion 710 may have triangular profiles, square profiles, rectangular profiles, octagonal profiles, oblong profile, or a profile having any other geometric shape.
- the insertion portion 708 of the catheter hub 404 includes the reduced diameter portion 422 of the catheter hub 404.
- the insertion portion 708, in certain embodiments, begins at the stopping surface 425 of the catheter hub 404 and extends to the treatment delivery end 704 of the catheter hub 404.
- the coupling portion 710 of the catheter hub 404 is positioned opposite the insertion portion 708 and includes the treatment receiving port 436.
- Anesthetics, medications, an electrical current, or any other treatment is received at the treatment receiving port 436 and delivered to the treatment delivery end 704 through a lumen 712 disposed through the catheter hub 404 from the treatment receiving end 702 to the treatment delivery end 704.
- the catheter receives the treatment and delivers it to a desired area such as the patient's sphenopalatine/pterygopalatine recess 118.
- the manipulation portion 706 of the catheter hub 404 in certain embodiments, has an increased diameter with respect to the insertion portion 708 and is positioned between the coupling portion 710 and the insertion portion 708.
- the increased diameter of the manipulation portion 706 of the catheter hub 404 facilitates manipulation of the catheter hub 404 by the physician or other medical professional.
- the arresting element 516 is coupled to and extends substantially perpendicularly from the outer surface 518 of the insertion portion 708 of the catheter hub 404.
- the arresting element 516 in one embodiment, includes a sloped surface 715.
- an end 711 of the arresting element 516 adjacent the treatment delivery end 704 of the catheter hub 404 extends from the outer surface 518 of the insertion portion 708 of the catheter hub 404 a distance that is substantially less than an end 714 of the arresting element 516 closer to the treatment receiving end 702 of the catheter hub 404.
- the sloped surface 715 of the arresting element 516 allows the flange of the arresting element 516 to be inserted past the stopping element 522 and into the recess of the engagement element 520.
- a rear surface 716 of the arresting element 516 extends substantially perpendicularly from the outer surface 518 of the reduced diameter portion 422 of the catheter hub 404.
- the interaction between the rear surface of the arresting element 516 and the stopping element 522 positions the catheter 412 within the sheath 420 such that the vertex 508 at the introduction end 505 of the sheath 420 aligns with a beginning of the curve of the rounded tip 510 of the catheter 412. In this position the transition 512 between the catheter 412 and the sheath 420 is continuous, smooth and substantially edge free.
- Figure 8 A depicts a side view of one embodiment of a catheter hub 404 and a catheter 412 according to the present disclosure.
- the threads of the coupling member 514 are more clearly illustrated.
- the coupling member 514 may be a snap fit attachment, a rim for chemically adhering a treatment delivery device, or any other means for attaching or affixing the treatment delivery device to the catheter hub 404.
- the catheter hub 404 includes a plurality of depth indicators 806 disposed along the insertion portion 708 of the catheter hub 404 at regular intervals.
- the depth indicators 806 are lines positioned around the circumference of the insertion portion 708 of the catheter hub 404.
- the depth indicators 806 may include other shapes, such as dots, squares, circles, triangles, or any other visual indicator.
- the depth indicators 806 may also include a numerical indication of a depth of the catheter hub 404 within the catheter hub receiving space 504.
- the physician or other medical professional advances the sheath 420 and the catheter 412 into the patient's nasal cavity 104. Once the insertion end 414 of the catheter has passed the anterior ridge 302 of the middle sinus turbinate 114, the physician or other medical professional advances the catheter hub 404 deeper within the catheter hub receiving space 504 causing the insertion end 414 of the catheter 412 to advance past the introduction end 505 of the sheath 420. Once the insertion end 414 of the catheter 412 is advanced to a position where the sheath 420 no longer contains the intrinsic curvature 416 of the catheter 412, the catheter 412 bends.
- the physician or other medical professional can direct the insertion end 414 of the catheter 412 into the sphenopalatine/pterygopalatine recess 118 to deliver a nerve block or other treatment to the sphenopalatine/pterygopalatine ganglia 120.
- the anatomy of a patient's nasal cavity 104 varies from individual to individual. Accordingly, certain patient's will have a deeper sphenopalatine/pterygopalatine recess 118 than others.
- the depth indicators 806 on the insertion portion 708 of the catheter hub 404 allow a physician or other medical professional to determine a depth of the insertion end 414 of the catheter 412 when the insertion end 414 of the catheter 412 is positioned within the patient's sphenopalatine/pterygopalatine recess 118.
- the physician or other medical professional may record a depth of the patient's sphenopalatine/pterygopalatine recess 118. In subsequent treatments of the patient's sphenopalatine/pterygopalatine ganglia 120, the physician or other medical professional can use the recorded depth as a guide.
- Figure 8B depicts a cutaway view of one embodiment of a catheter hub 404 according to the present disclosure. The embodiment depicted in Figure 8B is taken along line C-C of Figure 8 A.
- the catheter 412 is positioned within the lumen 712 in the catheter hub 404 and extends at least partially into the lumen 712. In other embodiments, the catheter 412 may be affixed to the end surface 802 at the treatment delivery end 704 of the catheter 412. In either embodiment, the catheter 412 is communicable in fluid communication with the lumen 712 to deliver medication, an anesthetic, or other chemical to the insertion end 414 of the catheter 412 where it can be dispensed to the patient.
- a electrical conduit such as a wire, is positioned through the lumen 712 in the catheter 412 and through a lumen 804 in the catheter.
- the electrical conduit may be coupled to an electrical source to deliver an electrical current to an electrode positioned at the insertion end 414 of the catheter 412.
- the electrode is configured to deliver the electrical current to the patient.
- Figure 9 A is an end view depicting one embodiment of a catheter hub 404 according to the present disclosure. The embodiment illustrated in Figure 9A is taken in the direction of the treatment receiving end 702 of the catheter hub 404.
- the catheter hub 404 includes one or more coupling flanges 902a and 902b positioned on an inner circumference 904 of the treatment receiving port 436.
- the coupling flanges 902 are configured to couple a syringe or other treatment delivery device to the catheter hub.
- Figure 9B is an end view depicting one embodiment of a catheter hub 404 according to the present disclosure. The embodiment illustrated in Figure 9A is taken in the direction of the treatment delivery end 704 of the catheter hub 404.
- FIG 10A depicts a top view of one embodiment of the sheath hub 402 coupled to a sheath 420 according to the present disclosure.
- the sheath hub 402 in certain embodiments, includes a catheter hub receiving end 1002 and a sheath receiving end 1004.
- the sheath 420 is coupled to the sheath receiving end 1004 of the sheath hub 402.
- the sheath hub 406 includes a substantially cylindrical portion 1006 and a tapered portion 1008. Disposed within the cylindrical portion 1006 is the catheter hub receiving space 504.
- the catheter hub receiving space 504 is also a substantially cylindrical void in the sheath hub 406.
- the insertion portion 708 of the catheter hub 404 is also cylindrical such that the insertion portion 708 of the catheter hub 404 may be received within the catheter hub receiving space.
- the shape of the insertion portion 708 of the catheter hub 404 and the shape of the void of the catheter hub receiving space 504 may be any other geometric shape while the outer surface 406 of the sheath hub 402 remains cylindrical.
- the outer surface 406 of the sheath hub 402 may be a shape other than cylindrical while the shape of the insertion portion 708 of the catheter hub 404 and the shape of the void of the catheter hub receiving space 504 are cylindrical.
- the tapered portion 1008 of the sheath hub 402 extends from the cylindrical portion 1006 to the sheath receiving end 1004 of the sheath hub 402.
- the diameter of the sheath hub 402 at the sheath receiving end 1004 is substantially smaller than the diameter of the sheath hub 402 at the interface 1010 between the cylindrical portion 1006 and the tapered portion 1008 such that the tappered portion 1008 of the sheath hub 402 is sloped towards the tappered portion 1008 of the sheath hub 402.
- a the sheath 420 may include a plurality of depth indicators 1016 disposed along at least a portion of an exterior surface 1018 of the sheath 420 at regular intervals.
- the depth indicators 1016 are lines positioned on the exterior surface 1018 of the sheath 420.
- the depth indicators 1016 may include other shapes, such as dots, squares, circles, triangles, or any other visual indicator.
- the depth indicators 1016 may also include a numerical indication of a depth of the sheath 420 when the sheath 420 is positioned within a patient's nasal cavity 104.
- a depth of the anterior ridge 302 of the middle sinus turbinate 114 varies from patient to patient.
- a physician or other medical professional may use the depth indicators 1016 on the sheath 420 to record a depth of the anterior ridge 302 of the middle sinus turbinate 114 for a particular patient.
- the physician or other medical professional may also record a depth of the inferior surface 304 of the nasal bone 122 for the patient.
- the physician or other medical professional can reference the recorded depths to avoid contacting or damaging the delicate tissues within the patient's nasal cavity 104.
- the physician or other medical professional may refer to a table (not shown) that lists an average depth anterior ridge 302 of the middle sinus turbinate 114 and an average depth of the inferior surface 304 of the nasal bone 122 for a patient according to certain characteristics of the patient.
- the table may list the average depth anterior ridge 302 of the middle sinus turbinate 114 and the average depth of the inferior surface 304 of the nasal bone 122 for a given age group.
- the table may also list an average depth of the sphenopalatine/pterygopalatine recess 118 for a given age group.
- the table may be further broken down into gender classifications.
- the table may list the average depths according to measurements taken on the patient's external nasal anatomy.
- Figure 10B depicts a cutaway view of one embodiment of a sheath hub 402 coupled to a sheath 420 according to the present disclosure. The embodiment depicted in Figure 10B is taken along line D-D of Figure 10A.
- the tapered portion includes a cavity 1012 that extends through the tapered portion from the catheter hub receiving space 504 in the sheath hub 402 to the sheath receiving end 1004 of the sheath hub 402.
- the sheath 420 is received within the cavity 1012 to couple the sheath to the sheath hub 402.
- the engagement element 520 is more clearly shown as a recess extending longitudinally along the interior surface 502 of the sheath hub 402.
- the recess of the engagement element 520 is only positioned within the cylindrical portion 1006 of the sheath hub 402.
- the recess of the engagement element 520 may extend from the stopping element 522 to the interface 1010 between the cylindrical portion 1006 and the tapered portion 1008.
- the recess of the engagement element 520 may extend through the tapered portion 1008 of the sheath hub 402.
- FIG 11 depicts an enlarged view of area 1014 of the sheath hub 402 which includes the stopping element 522 according to one embodiment of the present disclosure.
- the stopping element 522 includes a sloped surface 1102 disposed adjacent the catheter hub receiving end 1002 of the sheath hub 402. The sloped surface 1102 of the stopping element 522 may be engaged by the sloped surface 715 of the flange of the arresting element 516 to facilitate easy insertion of the insertion portion 708 of the catheter hub 404 into the catheter hub receiving space 504.
- the stopping element 522, the flange of the arresting element 516, or both may be made of a pliable or semi-pliable material to facilitate easy insertion of the insertion portion 708 of the catheter hub 404 into the catheter hub receiving space 504.
- the entire catheter hub 402, the entire sheath hub 402, or both may be made of a pliable or semi-pliable material.
- a stopping surface 1104 of the stopping element 522 extends substantially perpendicularly from the interior surface 502 of the sheath hub 402. When the catheter hub 404 is withdrawn from within the catheter hub receiving space 504 to the extended position 426, the stopping surface 1104 of the stopping element 522 engages the rear surface 716 of the arresting element 516 to stop further withdrawal of the catheter hub 404 from within the catheter hub receiving space 504.
- Figure 12 depicts an end view of one embodiment of the sheath hub 402 according to the present disclosure.
- the embodiment illustrated in Figure 12 is taken in the direction of the sheath receiving end 1004 of the sheath hub 402, the sheath 420 has been removed for clarity.
- the recess of the engagement element 520 extends through the tapered portion 1008 of the sheath hub 402 all the way to the sheath receiving end 1004.
- the recess of the engagement element 520 is aligned in the same rotational orientation with respect to a longitudinal axis of the sheath hub 402 as the rotational orientation indicator 408b.
- the recess of the engagement element 520 may be offset from the rotational orientation indicator 408b.
- Figure 13A illustrates a cutaway view of one embodiment of an introduction end 505 of the sheath 420 and an insertion end 414 of the catheter 412.
- the introduction end 505 of the sheath 420 and the insertion end 414 of the catheter 412 are positioned in the position that the introduction end 505 of the sheath 420 and the insertion end 414 of the catheter 412 are placed when the catheter hub 404 (not shown) is positioned in the extended position 426.
- the tip 510 of the insertion end 414 of the catheter 412 is curved 1306 such that the tip 510 is rounded.
- An outermost edge 1302 at the introduction end 505 of the sheath 420 is sloped to a vertex 508.
- the vertex 508 at the introduction end 505 of the sheath 420 is aligned with a beginning 1304 of the curve 1306 of the rounded tip 510 of the catheter 412.
- the transition 512 between the catheter 412 and the sheath 420 is continuous, smooth and substantially edge free.
- the fit between the catheter 412 and the sheath 420 is tight.
- a lack of a gap between the catheter 412 and the sheath 420 reduces the likelihood that the vertex 508 at the introduction end 505 of the sheath 420 will snag or otherwise damage the delicate tissues within the nasal cavity 104 of the patient.
- Figure 13B illustrates a cutaway view of one embodiment of an introduction end 505 of the sheath 420 and an insertion end 414 of the catheter 412.
- the outer diameter 1308 of the catheter 412 is substantially smaller than the inner diameter 1310 of the sheath 1420.
- the transition 512 between the catheter 412 and the sheath 420 is not smooth and the vertex 508 on the introduction end 505 of the sheath 420 may form a sharp edge that may snag or otherwise damage the delicate tissues within the nasal cavity 104 of the patient.
- the catheter 412 and the sheath 420 may be designed such that the fit between the catheter 412 and the sheath 420 is tight to avoid sharp edges.
- Figure 13C illustrates a cutaway view of another embodiment of an introduction end 505 of the sheath 420 and an insertion end 414 of the catheter 412.
- the catheter 412 is positioned within the sheath 420 at a position that causes the vertex 508 of the sheath 420 to extend beyond the beginning 1304 of the curve 1306 at the insertion end 414 of the catheter 412.
- the transition 512 between the catheter 412 and the sheath 420 is not smooth and the vertex 508 on the introduction end 505 of the sheath 420 may form a sharp edge that may snag or otherwise damage the delicate tissues within the nasal cavity 104 of the patient.
- the stopping element 522 stops the withdrawal of the catheter hub 404 from within the catheter hub receiving space 504 at a position that aligns the vertex 508 on the introduction end 505 of the sheath 420 with the beginning 1304 of the curve 1306 at the insertion end 414 of the catheter 412.
- AD a highway patrolman, suffered 8/10 headaches virtually every day for years. He remained headache free for two months after SPGB. Remembering in those two months how good life could be without headaches, he tearfully requested a repeat procedure when his headaches returned. He now has a brief, painless, bi-monthly procedure and lives headache free. [0128] Likewise, certain types of headaches are a consequence of nerve dysfunction, disrupting the dysfunctional circuits can act as a reset, allowing normal nerve function to return. For this reason, the benefit of a SPGB may last for an indefinite period of time, far beyond the effect of the local anesthetic. Accordingly, it has been learned that many patients experience an increased benefit when the procedure is repeated.
- the SphenoCathTM brand of medical device has the potential to eclipse most, if not all, published study results, simply because it more precisely and consistently delivers medication to the desired location.
- Direct fluoroscopy has documented the ability of the SphenoCathTM brand of medical device to deliver an infusion to the target.
- the SphenoCathTM brand of medical device extends the opportunity for SPGB from a small contingent of pain specialists, to the office practitioner, exponentially increasing patient access to the procedure.
- the vertex 508 at the introduction end 505 of the sheath 420 is shielded from the delicate tissues within the nasal cavity 104 of the patient by the rounded side wall 1314 of the bulbous tip area 1310.
- an outer diameter 1316 of the sheath 420 may be substantially smaller than an outermost diameter 1318 of the bulbous tip area 1310 such that the bulbous tip area shields the introduction end 505 of the sheath 420 from potential snags or other damage to the delicate tissues within the nasal cavity 104 of the patient.
- the introduction end 505 may be squared off or rounded rather than sloped as illustrated in the depicted embodiment.
- each of the various elements of the disclosure and claims may also be achieved in a variety of manners.
- This disclosure should be understood to encompass each such variation, be it a variation of an implementation of any apparatus implementations, a method or process implementations, or even merely a variation of any element of these.
- each physical element should be understood to encompass a disclosure of the action which that physical element facilitates.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dentistry (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgical Instruments (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014556530A JP2015507964A (en) | 2012-02-10 | 2012-02-29 | System and apparatus for facilitating intranasal treatment of a patient |
CN201280054015.5A CN104168846B (en) | 2012-02-10 | 2012-02-29 | Beneficial to the system and apparatus of patient's intranasal treatment |
CA2846226A CA2846226C (en) | 2012-02-10 | 2012-02-29 | Systems and apparatus for facilitating intranasal treatment of a patient |
EP12867745.7A EP2734129B1 (en) | 2012-02-10 | 2012-02-29 | Apparatus for facilitating intranasal treatment of a patient |
ES12867745T ES2713971T3 (en) | 2008-09-04 | 2012-02-29 | Apparatus to facilitate the intranasal treatment of a patient |
AU2012369170A AU2012369170A1 (en) | 2012-02-10 | 2012-02-29 | Systems and apparatus for facilitating intranasal treatment of a patient |
KR20147022030A KR20140145576A (en) | 2012-02-10 | 2012-02-29 | Systems and apparatus for facilitating intranasal treatment of a patient |
MX2014009606A MX2014009606A (en) | 2012-02-10 | 2012-02-29 | Systems and apparatus for facilitating intranasal treatment of a patient. |
IL233418A IL233418B (en) | 2012-02-10 | 2014-06-26 | Systems and apparatus for facilitating intranasal treatment of a patient |
HK15104977.2A HK1204440A1 (en) | 2012-02-10 | 2015-05-26 | Systems and apparatus for facilitating intranasal treatment of a patient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/371,288 US10166351B2 (en) | 2008-09-04 | 2012-02-10 | Enhanced systems, processes and apparatus for facilitating intranasal treatment of a patient and products thereby |
US13/371,288 | 2012-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013119258A1 true WO2013119258A1 (en) | 2013-08-15 |
Family
ID=48947879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/027138 WO2013119258A1 (en) | 2008-09-04 | 2012-02-29 | Systems and apparatus for facilitating intranasal treatment of a patient |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2734129B1 (en) |
JP (1) | JP2015507964A (en) |
KR (1) | KR20140145576A (en) |
CN (1) | CN104168846B (en) |
AU (1) | AU2012369170A1 (en) |
CA (1) | CA2846226C (en) |
HK (1) | HK1204440A1 (en) |
IL (1) | IL233418B (en) |
MX (1) | MX2014009606A (en) |
WO (1) | WO2013119258A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015077445A1 (en) * | 2013-11-21 | 2015-05-28 | Jet Medical, Inc. | System for facilitating intranasal guidance |
JP2015202166A (en) * | 2014-04-11 | 2015-11-16 | 昭裕 森 | Pretreatment instrument for transnasal endoscope |
WO2016035509A1 (en) * | 2014-09-05 | 2016-03-10 | オリンパス株式会社 | Treatment tool for endoscope, treatment tool unit and treatment system |
USD767128S1 (en) | 2014-02-19 | 2016-09-20 | Jet Medical, Inc. | Sheath over catheter |
US20170135723A1 (en) * | 2015-10-14 | 2017-05-18 | Christopher Zarembinski | Integrated needle-catheter systems and methods of use |
US11324934B2 (en) | 2020-01-07 | 2022-05-10 | Sana Louis Bloch | Deep nasal insertion sphenopalatine ganglion (“SPG”) treatment |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016117432A1 (en) * | 2015-01-20 | 2016-07-28 | オリンパス株式会社 | Insertion assistance tool and medical device |
CA3234408A1 (en) * | 2015-05-12 | 2016-11-17 | National University Of Ireland Galway | Devices for therapeutic nasal neuromodulation and associated methods and systems |
US10820923B2 (en) * | 2016-05-16 | 2020-11-03 | Biosense Webster (Israel) Ltd. | Insertion tube with deflectable tip |
WO2017218854A1 (en) * | 2016-06-15 | 2017-12-21 | Arrinex, Inc. | Devices and methods for treating a lateral surface of a nasal cavity |
CN107684657B (en) * | 2017-08-17 | 2020-09-01 | 陈翔 | Double-layer elbow micro catheter for artery chronic occlusion lesion interventional operation |
KR102048413B1 (en) * | 2017-08-18 | 2019-11-26 | 주식회사 제노스 | Support catheter |
KR101982450B1 (en) * | 2018-10-08 | 2019-05-24 | 오민철 | Endoscope guide device for nasal cavity and endoscope treatment apparatus having the same |
US11684414B2 (en) | 2018-12-11 | 2023-06-27 | Neurent Medical Limited | Systems and methods for therapeutic nasal neuromodulation |
JPWO2021044923A1 (en) * | 2019-09-02 | 2021-03-11 | ||
US11883091B2 (en) | 2020-04-09 | 2024-01-30 | Neurent Medical Limited | Systems and methods for improving sleep with therapeutic nasal treatment |
WO2021205230A1 (en) | 2020-04-09 | 2021-10-14 | Neurent Medical Limited | Systems and methods for therapeutic nasal treatment |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830189A (en) * | 1995-06-07 | 1998-11-03 | Johnson & Johnson Medical, Inc. | Catheter hub to nose engagement |
US20040015068A1 (en) * | 2000-05-08 | 2004-01-22 | Alon Shalev | Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the bbb and cerebral blood flow |
US20070021648A1 (en) * | 2005-06-29 | 2007-01-25 | Jay Lenker | Transluminal sheath hub |
US7632243B2 (en) * | 2005-08-08 | 2009-12-15 | Smiths Medical Asd, Inc. | Duckbill catheter release mechanism |
US20100030187A1 (en) * | 2008-08-01 | 2010-02-04 | Tian Xia | Apparatus and Method for Controlling Headaches |
US20100057048A1 (en) * | 2008-09-04 | 2010-03-04 | Stephen Eldredge | Apparatus, System, and Method for Treating Atypical Headaches |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070038187A1 (en) * | 2005-08-08 | 2007-02-15 | Albert Sean J | Needle guard mechanism with anti-rotation feature |
US7799035B2 (en) * | 2005-11-18 | 2010-09-21 | Carefusion 2200, Inc. | Device, system and method for delivering a curable material into bone |
JP5086648B2 (en) * | 2007-01-19 | 2012-11-28 | オリンパスメディカルシステムズ株式会社 | Treatment tool |
AU2009231645A1 (en) * | 2008-04-02 | 2009-10-08 | Laurimed, Llc | Methods and devices for delivering injections |
US8231588B2 (en) * | 2008-08-01 | 2012-07-31 | Tian Xia | Methods for ameliorating pain and devices for delivering a medicament |
US8905980B2 (en) * | 2008-08-01 | 2014-12-09 | Tian Xia | Devices for delivering a medicament and methods for ameliorating pain |
US20120029525A1 (en) * | 2010-07-27 | 2012-02-02 | Frommer J Pedro | Medical device and method for vascular access |
-
2012
- 2012-02-29 WO PCT/US2012/027138 patent/WO2013119258A1/en active Application Filing
- 2012-02-29 CN CN201280054015.5A patent/CN104168846B/en not_active Expired - Fee Related
- 2012-02-29 MX MX2014009606A patent/MX2014009606A/en unknown
- 2012-02-29 KR KR20147022030A patent/KR20140145576A/en not_active Application Discontinuation
- 2012-02-29 JP JP2014556530A patent/JP2015507964A/en not_active Withdrawn
- 2012-02-29 AU AU2012369170A patent/AU2012369170A1/en not_active Abandoned
- 2012-02-29 CA CA2846226A patent/CA2846226C/en not_active Expired - Fee Related
- 2012-02-29 EP EP12867745.7A patent/EP2734129B1/en not_active Not-in-force
-
2014
- 2014-06-26 IL IL233418A patent/IL233418B/en active IP Right Grant
-
2015
- 2015-05-26 HK HK15104977.2A patent/HK1204440A1/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830189A (en) * | 1995-06-07 | 1998-11-03 | Johnson & Johnson Medical, Inc. | Catheter hub to nose engagement |
US20040015068A1 (en) * | 2000-05-08 | 2004-01-22 | Alon Shalev | Method and apparatus for stimulating the sphenopalatine ganglion to modify properties of the bbb and cerebral blood flow |
US20070021648A1 (en) * | 2005-06-29 | 2007-01-25 | Jay Lenker | Transluminal sheath hub |
US7632243B2 (en) * | 2005-08-08 | 2009-12-15 | Smiths Medical Asd, Inc. | Duckbill catheter release mechanism |
US20100030187A1 (en) * | 2008-08-01 | 2010-02-04 | Tian Xia | Apparatus and Method for Controlling Headaches |
US20100057048A1 (en) * | 2008-09-04 | 2010-03-04 | Stephen Eldredge | Apparatus, System, and Method for Treating Atypical Headaches |
Non-Patent Citations (1)
Title |
---|
See also references of EP2734129A4 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180256849A1 (en) * | 2013-11-21 | 2018-09-13 | Jet Medical, Inc. | System for facilitating intranasal guidance |
US9993612B2 (en) | 2013-11-21 | 2018-06-12 | Jet Medical, Inc. | Method for facilitating intranasal guidance |
AU2014352997B2 (en) * | 2013-11-21 | 2017-11-30 | Jet Medical, Inc. | System for facilitating intranasal guidance |
JP2017500095A (en) * | 2013-11-21 | 2017-01-05 | ジェット・メディカル・インコーポレイテッドJet Medical,Inc. | System for facilitating navigation in the nasal cavity |
US9839770B2 (en) | 2013-11-21 | 2017-12-12 | Jet Medical, Inc. | System and method for facilitating intranasal guidance |
US10518065B2 (en) | 2013-11-21 | 2019-12-31 | Jet Medical Inc. | Method for facilitating intranasal guidance |
AU2018200766B2 (en) * | 2013-11-21 | 2018-12-20 | Jet Medical, Inc. | System for facilitating intranasal guidance |
US9849265B2 (en) | 2013-11-21 | 2017-12-26 | Jet Medical, Inc. | Method for facilitating intranasal guidance |
AU2018200764B2 (en) * | 2013-11-21 | 2018-12-06 | Jet Medical, Inc. | System for facilitating intranasal guidance |
WO2015077445A1 (en) * | 2013-11-21 | 2015-05-28 | Jet Medical, Inc. | System for facilitating intranasal guidance |
US9999747B2 (en) | 2013-11-21 | 2018-06-19 | Jet Medical, Inc. | System for facilitating intranasal guidance |
USD767128S1 (en) | 2014-02-19 | 2016-09-20 | Jet Medical, Inc. | Sheath over catheter |
JP2015202166A (en) * | 2014-04-11 | 2015-11-16 | 昭裕 森 | Pretreatment instrument for transnasal endoscope |
JP2017074465A (en) * | 2014-09-05 | 2017-04-20 | オリンパス株式会社 | Treatment tool for endoscope, treatment tool unit and treatment system |
WO2016035509A1 (en) * | 2014-09-05 | 2016-03-10 | オリンパス株式会社 | Treatment tool for endoscope, treatment tool unit and treatment system |
CN106687055A (en) * | 2014-09-05 | 2017-05-17 | 奥林巴斯株式会社 | Treatment tool for endoscope, treatment tool unit and treatment system |
JPWO2016035509A1 (en) * | 2014-09-05 | 2017-04-27 | オリンパス株式会社 | Endoscopic treatment tool, treatment tool unit, and treatment system |
US10524640B2 (en) | 2014-09-05 | 2020-01-07 | Olympus Corporation | Endoscopic treatment instrument, treatment instrument unit, and treatment system |
JP6082169B2 (en) * | 2014-09-05 | 2017-02-15 | オリンパス株式会社 | Endoscopic treatment tool, treatment tool unit, and treatment system |
US20170135723A1 (en) * | 2015-10-14 | 2017-05-18 | Christopher Zarembinski | Integrated needle-catheter systems and methods of use |
US11547437B2 (en) | 2015-10-14 | 2023-01-10 | Christopher Zarembinski | Integrated needle-catheter systems and methods of use |
US10342576B2 (en) * | 2015-10-14 | 2019-07-09 | Christopher Zarembinski | Integrated needle-catheter systems and methods of use |
US11324934B2 (en) | 2020-01-07 | 2022-05-10 | Sana Louis Bloch | Deep nasal insertion sphenopalatine ganglion (“SPG”) treatment |
Also Published As
Publication number | Publication date |
---|---|
EP2734129B1 (en) | 2019-01-09 |
IL233418A0 (en) | 2014-08-31 |
IL233418B (en) | 2019-07-31 |
CN104168846B (en) | 2017-11-14 |
EP2734129A4 (en) | 2015-06-24 |
CN104168846A (en) | 2014-11-26 |
AU2012369170A1 (en) | 2014-07-24 |
HK1204440A1 (en) | 2015-11-20 |
JP2015507964A (en) | 2015-03-16 |
CA2846226A1 (en) | 2013-08-15 |
CA2846226C (en) | 2019-03-19 |
KR20140145576A (en) | 2014-12-23 |
MX2014009606A (en) | 2015-05-11 |
EP2734129A1 (en) | 2014-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2846226C (en) | Systems and apparatus for facilitating intranasal treatment of a patient | |
US20190054262A1 (en) | Enhanced systems, processes and apparatus for facilitating intranasal treatment of a patient and products thereby | |
US8388600B1 (en) | Apparatus, system, and method for treating atypical headaches | |
JP6122021B2 (en) | Catheter positioning system | |
Mariano et al. | Ultrasound guidance versus electrical stimulation for infraclavicular brachial plexus perineural catheter insertion | |
US20150290439A1 (en) | Methods for bilateral central autonomic neuromodulation | |
Mariano et al. | Interscalene perineural catheter placement using an ultrasound-guided posterior approach | |
Boezaart | Continuous interscalene block for ambulatory shoulder surgery | |
AU2017208333B2 (en) | Systems and apparatus for facilitating intranasal treatment of a patient | |
EP2091604B1 (en) | Catheter positioning system | |
US20090216202A1 (en) | Delivery needle apparatus with sleeve | |
WO2022026762A1 (en) | Apparatus, system, and method for facilitating intranasal treatment of a patient | |
US11839731B2 (en) | Catheter for deep nasal insertion sphenopalatine ganglion (“SPG”) treatment | |
Day et al. | Infraclavicular brachial plexus block and infusion for treatment of long-standing complex regional syndrome type 1: a case report | |
CN213666114U (en) | Needle head for intrastromal corneal injection | |
Oh et al. | Using an Epistim® catheter for a continuous epidural block for treating pain from herpes zoster or postherpetic zoster neuralgia | |
Patil et al. | Comparison of success rate of classical supraclavicular brachial plexus block with and without nerve stimulator | |
Orr et al. | Another eye-protection option | |
Habibi et al. | Craniofacial Pain: Occipital Neuralgia and Nerve Block | |
Jalili et al. | Comparison of the Effect of Adding Magnesium Sulfate and Low-Dose Dexamethasone to Ropivacaine for Supraclavicular Brachial Plexus (Trunks) Nerve Block in Elective Upper Limb Surgeries: A Prospective Triple-Blind Randomized Clinical Trial | |
CN112168480A (en) | Needle head for intrastromal corneal injection | |
NONSTIMULATING | CONtiNUOUS PERiPhERAl NERvE BlOckS | |
Shariat et al. | Hadzic's Peripheral Nerve Blocks and Anatomy for Ultrasound-Guided Regional Anesthesia, 2nd |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12867745 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2846226 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012867745 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014556530 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 233418 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2012369170 Country of ref document: AU Date of ref document: 20120229 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147022030 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/009606 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |